Roche, Discuva In Up To $191 Million+ Antibacterial Collaboration

Roche said today it will use Discuva’s (Selective Antibiotic Target IdentificatioN) SATIN technology platform to discover and develop new antibiotics for infections caused by multi-drug resistant Gram-negative bacteria, under a collaboration that could generate $191 million-plus for the British biotech. Discuva will use SATIN on the bacteriocidal hits identified via high-throughput phenotypic screening of chemical classes which hit molecular targets distinct from those already known to interact with existing antibiotics. The screening enables Discuva to identify both the molecular target(s) of each compound and all the corresponding potential resistance gene(s).

Help employers find you! Check out all the jobs and post your resume.